SynthesisCurrent oncology (Toronto, Ont.)2025

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.

Filip Marković et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.